Prostate Cancer | Charles J Ryan, MD

Prostate Cancer Update, Issue 2, 2021 — Part 1: Our interview with Dr Ryan highlights the following topics as well as cases from his practice:

• Practical factors influencing the selection of therapy for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) (0:00)
• Case: A man in his late 60s with nmCRPC receives first-line therapy with abiraterone (29:53)
• Case: A man with CRPC and high microsatellite instability attains a dramatic response to pembrolizumab (37:31)
• Perspective on the use of adjuvant radiation and salvage radiation therapy for patients with prostate cancer (46:10)
• PSMA (prostate-specific membrane antigen)-targeted PET scanning in prostate cancer; therapeutic approach to M0 disease in patients who experience disease progression on androgen deprivation therapy (48:49)
• Benefits of early initiation of secondary hormonal therapy (57:06)
• Counseling patients about therapeutic options for mHSPC; considerations for clinical care in the COVID-19 era (1:01:08)
• Choice of secondary hormonal therapy for patients with metastatic prostate cancer (1:09:21)
• Selection and sequencing of therapy for patients with mCRPC (1:12:03)
• Management of disease that progresses on androgen receptor (AR)-targeted therapy; CARD trial of cabazitaxel versus AR-targeted agents for patients with previously treated mCRPC (1:16:34)
• Role of chemotherapy and PARP inhibitors for patients with prostate cancer and DNA damage repair gene alterations (1:20:02)

CME information and select publications